| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $15,682 | 1 | 100 |
| Piccina Cintia | U.S. CCO & Country Gen Manager | 0 | $0 | 1 | $15,682 | $-15,682 |
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a …
Over the last 12 months, insiders at Autolus Therapeutics plc have bought $0 and sold $15,682 worth of Autolus Therapeutics plc stock.
On average, over the past 5 years, insiders at Autolus Therapeutics plc have bought $0 and sold $15,682 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-09-02 | Sale | Piccina Cintia | U.S. CCO & Country Gen Manager | 6,713 0.0026% | $2.34 | $15,682 | -19.20% |
| Increased Positions | 41 | +35.04% | 17M | +11.83% |
| Decreased Positions | 48 | -41.03% | 15M | -10.77% |
| New Positions | 15 | New | 8M | New |
| Sold Out Positions | 20 | Sold Out | 7M | Sold Out |
| Total Postitions | 110 | -5.98% | 142M | +1.06% |